<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83761">
  <stage>Registered</stage>
  <submitdate>29/03/2009</submitdate>
  <approvaldate>21/05/2009</approvaldate>
  <actrnumber>ACTRN12609000316202</actrnumber>
  <trial_identification>
    <studytitle>Pain Relief after Hip Replacement Surgery:  A comparison of two approaches</studytitle>
    <scientifictitle>Optimising Pain Relief after Hip Replacement Surgery:  A comparison of Patient Controlled Lumbar Plexus Block and Patient Controlled Iintravenous (IV) Opioid Analgesia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>THJR09</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain relief after hip replacement surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patient controlled continuous lumbar plexus block (ropivacaine 0.2% 5 ml/hr with as required 5 ml boluses via a catheter inserted near the lumbar plexus) during the first 48 postoperative hours after hip replacement surgery</interventions>
    <comparator>Subarachnoid block (bupivacaine 0.5% 2.5 mL) with Patient controlled intravenous opioid (morphine) analgesia during the first 48 postoperative hours after hip replacement surgery</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain after hip replacement surgery, assessed by patient interrogation regarding analgesic consumption pain scores using numerical rating pain score (NRPS).</outcome>
      <timepoint>1-2 days postoperatively.  Analgesic requirements and pain scores measured in the afternoon of Day 1 and Day 2 following surgery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Postoperative antiemetic consumption</outcome>
      <timepoint>First 48 postoperative hours every 24 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Procedural time</outcome>
      <timepoint>At time of procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient physiotherapy endpoints: 
Bed-to-chair: yes/no
Bed-to-bathroom: yes/no
Walk &gt; 12 metres: yes/no</outcome>
      <timepoint>Daily for first 2 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients requiring analgesia following hip replacement surgery under the care of the three investigators</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patient refusal of either block.  2. Known neuropathy involving the leg undergoing surgery.  3. Known allergy to amide local anaesthetic drugs.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Initial invitation to participate in the study will occur in the surgeon's rooms.  Approximately one week prior to surgery, patients will be contacted by a research assistant to provide further informed consent.  Written informed consent will be obtained from all patients.  
Assignment of the patient to lumbar plexus block or IV opioid analgesia will be delivered in a sealed opaque envelope.</concealment>
    <sequence>A computerised random number generator will be used to assign the patient to one of the 2 groups.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2009</anticipatedstartdate>
    <actualstartdate>15/04/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/04/2013</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Michael Fredrickson</primarysponsorname>
    <primarysponsoraddress>Anaesthesia Institute,
P O Box 109 199,
Newmarket,
Auckland 1149</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Auckland Medical Research Foundation</fundingname>
      <fundingaddress>P O Box 110139 Auckland Hospital Auckland 1148</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>If the primary hypothesis is confirmed, this study will provide evidence supporting the Patient Controlled Lumbar Plexus Block for postoperative analgesia for total hip replacement surgery.  Increased exposure of the techniques may promote their uptake in this setting.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Y Regional Ethics Committee</ethicname>
      <ethicaddress>P O Box 1031,
Hamilton,
Waikato Mail Centre 3240</ethicaddress>
      <ethicapprovaldate>21/05/2009</ethicapprovaldate>
      <hrec>NTY/09/03/029</hrec>
      <ethicsubmitdate>5/03/2009</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>michaelfredrickson@yahoo.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>anaesthesiainstitute@yahoo.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Linda White</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>anaesthesiainstitute@yahoo.com</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1050
</address>
      <phone>+645221117</phone>
      <fax />
      <email>michaelfredrickson@yahoo.com</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>